T2 Biosystems stock is moving after the company announced today that the United States Centers for Medicare & Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for the T2Bacteria┬« Panel for FY 2020.

The T2Bacteria Panel, the first and only FDA-cleared test to identify sepsis-causing bacterial pathogens directly from whole blood in 3 to 5 hours without the need to wait for blood culture, is now also the first and only in-vitro diagnostic test to ever receive approval for NTAP.  In its FY 2020 inpatient prospective payments system fin...